Tay Salimullah Email & Phone Number

Chicago, Il, Us

London, England, Gb

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector which is comprised of cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

Washington, District Of Columbia, Us

Providing strategic counsel on ethics in genomic medicines, including pricing, access, industrialization, ultra-rare diseases, and advanced MedTech innovation. ARM is the global advocacy leader for genetic medicines, with a mission to enable durable, potentially curative therapies for patients worldwide. Representing 400+ members across 25 countries, uniting biotech innovators, researchers, and patient groups to drive policy, data insights, and healthcare modernization.

Trogenix leverages cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to pioneer next-generation cancer treatments. Using proven AAV vectors, our proprietary Synthetic Super-Enhancers (SSEs) target tumour cells with unmatched precision, exposing cancer to the immune system and destroying tumour cells. For any escaping cells, our 'Trojan horse' technology reawakens immunity, offering potentially curative, one-time treatments. With preclinical glioblastoma data showing curative potential, Trogenix is set to transform cancer care and explore applications beyond oncology.

“Renovamen” derived from Latin, meaning “renewal” or “restoration.” It signifies the process of revitalization. Renovamen provides consulting and board services to early-stage biotech companies, venture capital, and private equity firms. Focused on MedTech. Recent projects inc. corp. strategy, US & global forecasting, evaluation of early-stage indications and strategic pricing.

Basel, Baselstadt, Ch

Member of the executive committee. Built industry leading capabilities transforming AveXis from $8.7B acquisition into a pioneering worldwide multibillion-dollar gene therapy/rare disease business (neuroscience, retina gene therapy and Immunology).

Basel, Basel-Town, Ch

Lead enterprise wide global-health-access programs. Incubated and executed the Novartis Africa Sickle Cell Flagship Program.

Basel, Baselstadt, Ch

Characterization of real-world patient population and market access impact, following landmark results of a Phase III study which showed that targeting inflammation with ACZ885 reduces patients' risk of cardiovascular disease.

Basel, Baselstadt, Ch

Strongly contributed incubating the CAR-T business for Novartis. Developed and guided the organization on global value story for CAR-T- the first FDA approved CAR-T cell therapy.

Basel, Switzerland, Ch

Spearheaded disruptive $40m real-world-data public-private-partnership to shape access for personalized cancer therapies (partners include, 8 biopharma companies, physicians, payers, regulators, and European Hematology Association).

Basel, Baselstadt, Ch

Responsible for integrated commercial market access (in market and pipeline) execution $2 billion portfolio of small molecules and innovative biologics across 28 markets.

Developed pricing and market access strategy for a US based company commercializing assets in ex Chinese Asian markets including (Australia, Philippines, Indonesia, Singapore, Malaysia, Vietnam, Thailand, Taiwan & Korea).

Singapore, Singapore, Sg

The Clermont Group (previously Chandler Corp.) is a private $billion investment group based in Singapore. Since 1986, investing in globally in public and private equity across a range of industries, including energy, financial services, consumer, and healthcare.

New York, New York, Us

New York, New York, Us

New York, New York, Us

New York, New York, Us

New York, New York, Us

Washington, District Of Columbia, Us

Pfizer Global Health Fellowship (in partnership with Boston School of Public Health). Worked with USAID to scale up a HIV data informatics program across Malawi.

New York, New York, Us

Pfizer Global Health Fellowship (Class 10), International Public Health

Bsc Business Management Studies